by Kevin McMahon | Jan 21, 2018 | News & Opinions, Science
Longeveron is currently enrolling subjects in its Phase 2b multi-center clinical trial designed to test the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) for the treatment of subjects with clinically diagnosed with Aging Frailty. This is the only...
by Kevin McMahon | Jan 21, 2018 | News & Opinions, Science
Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease. Longeveron’s Phase I, prospective, randomized, placebo-controlled, double-blinded study is designed to test the safety and efficacy of Longeveron Mesenchymal Stem...
by Kevin McMahon | Jan 21, 2018 | News & Opinions, Science
America is facing one of the worst influenza seasons in recent history. The influenza virus is one of the top ten causes of death in elderly people. Longeveron is conducting a multi-center, randomized, placebo controlled trial using its Longeveron Mesenchymal Stem...
by Bernard Siegel | Jun 6, 2017 | News & Opinions, Science
On December 2016, Mayor Bill De Blasio announced that the city’s next great industry is biotechnology. A lofty goal grounded in reality and backed with a $500 million funding commitment. Not long after this announcement, in April 2017, I visited New York to witness...
by Bernard Siegel | May 23, 2017 | News & Opinions, Science
Twelve years ago my nonprofit organization founded an annual conference that evolved into the World Stem Cell Summit. Over time, this event has brought together thousands of thought leaders and stakeholders from around the globe. All came with a shared passion, to...
by Eve Herold | May 18, 2017 | News & Opinions, Science
Stem cells have been lauded for their potential to cure a large array of cell based conditions, from muscular dystrophy to cancer to Parkinson’s Disease. But they have another, lesser known use: as tools for research into how human cells respond to an almost limitless...
